CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
Sanjeev is currently the Country President for AstraZeneca Malaysia
35 million mosquito nets supplied to countries in sub-Saharan Africa through partners
The company will set-up a pharmaceuticals formulation manufacturing unit with an investment of Rs. 100 crore in Odisha
Move to increase affordability and accessibility for heart failure patients across the country
New Lexington, Massachusetts facility to provide customer education and collaboration opportunities
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Subscribe To Our Newsletter & Stay Updated
